A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes

Diabetologia

Volumn 42, Issue 4, 1999, Pages 472-479

  Soulis, T ^a,c   Sastra, S ^a   Thallas, V ^a   Mortensen, S B ^b   Wilken, M ^b   Clausen, J T ^b   Bjerrum, O J ^b   Petersen, H ^b   Lau, J ^b   Jerums, G ^a   Boel, E ^b   Cooper, M E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NOVO NORDISK A S   (Denmark)

^c AUSTIN HEALTH   (Australia)

Author keywords

Advanced glycation end products; Aminoguanidine; Experimental diabetes mellitus; Mesenteric arteries

Indexed keywords

AMINOGUANIDINE; AMINOPHENAZONE;

ANIMAL TISSUE; ARTICLE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; EXPERIMENTAL DIABETES MELLITUS; EXTRACELLULAR MATRIX; GLYCATION; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MESENTERIC ARTERY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; VASCULAR DISEASE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; ENZYME INDUCTION; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERTROPHY; MALE; MESENTERIC ARTERIES; MESENTERIC VEINS; MICE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PHENAZINES; RABBITS; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032980370     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051181     Document Type: Article

References (33)

1. Williamson JR, Tilton RG, Chang K, Kilo C (1988) Basement membrane abnormalities in diabetes mellitus: relationship to clinical microangiopathy. Diabetes Metab Rev 4: 339-370
2. Cerami A, Vlassara H, Brownlee M (1988) Role of advanced glycosylation products in complications of diabetes. Diabetes Care 1: 73-79
3. Makita Z, Vlassara H, Rayfield E et al. (1992) Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258: 651-653
4. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334
5. Hammes H, Martin S, Federlin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88: 11555-11558
6. Rumble JR, Cooper ME, Soulis T et al. (1997) Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest 99: 1016-1027
7. Corbett JA, Tilton RG, Chang K et al. (1992) Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552-556
8. Manassen J, Kalif S (1966) Organic Polymers. Correlation between Their Structure and Catalytic Activity in Heterogeneous Systems. II. Models for Dehydrogenation Catalysts. J Am Chem Soc 88: 1943-1947
9. Monnier V, Vishwanath V, Frank K, Elmets G, Dauchot P, Kohn R (1986) Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314: 403-408
10. Reddy S, Bichler J, Wells KK, Thorpe SR, Baynes JW (1995) N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878
11. Bjerrum OJ, Inglid A, Lowenstein H, Weeke B (1973) Quantitation of human IgG by rocket immunoelectrophoresis at pH5.0 by use of caramylated antibodies: a routine laboratory method. Clin Chim Acta 46: 337-343
12. Kohler G, Milstein C (1976) Derivation of specific antibody-producing tissue culture and tumour lines by cell fusion. Eur J Immunol 6: 511-519
13. Taggart RT, Samloff IM (1983) Stable antibody-producing murine hybridomas. Science 219: 1228-1230
14. Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267: 5133-5138
15. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G (1996) The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 50: 627-634
16. Soulis T, Cooper ME, Sastra S et al. (1997) Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 40: 1141-1151
17. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41: 1286-1292
18. Prabhakaram M, Ortwerth B (1994) Determination of glycation cross-linking by the sugar-dependent incorporation of (C-14) lysine into protein. Anal Biochem 216: 305-312
19. Karlsen AE, Andersen HU, Vissing H et al. (1995) Cloning and expression of cytokine-inducible nitric oxide synthase cDNA from rat islets of Langerhans. Diabetes 44: 753-758
20. Bredt DS, Snyder SH (1989) Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 86: 9030-9033
21. Amin AR, Attur MG, Thakker GD et al. (1996) A novel mechanism of action of tetracyclines - effects on nitric oxide synthases. Proc Natl Acad Sci USA 93: 14014-14019
22. Bunag R (1973) Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34: 279-282
23. Salacinski P, McLean C, Sykes J, Clement-Jones W, Lowry P (1981) Iodination of proteins, glycoproteins and peptides using a solid phase oxidising agent, 1,3,4,6-1,3,4,6-tetrachloro-3 a,6a-diphenylglycoluril. Anal Biochem 117: 136-146
24. Soulis T, Thallas V, Youssef S et al. (1997) Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia 40: 619-628
25. Nakane M, Pollock JS, Klinghofer V et al. (1995) Functional expression of three isoforms of human nitric oxide synthase in baculovirus-infected insect cells. Biochem Biophys Res Commun 206: 511-517
26. Rumble J, Komers R, Cooper M (1995) Kinins or nitric oxide, or both, are involved in the antitropic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens 14: 601-607
27. Shikata K, Makino H, Sugimoto H et al. (1995) Localization of advanced glycation endproducts in the kidney of experimental diabetic rats. J Diabetes Complications 9: 269-271
28. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA (1991) Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 88: 6107-6111
29. Hogan M, Cerami A, Bucala R (1992) Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 90: 1110-1115
30. Brownlee M (1994) Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 43: 836-841
31. Cameron NE, Cotter MA (1995) Neurovascular dysfunction in diabetic rats - potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 96: 1159-1163
32. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G (1995) The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38: 387-394
33. Kochakian M, Manjula BN, Egan JJ (1996) Chronic dosing with aminoguanidine and novel advanced glycosylation end product formation inhibitors ameliorates cross-linking of tail tendon collagen in streptozotocin-induced diabetic rats. Diabetes 45: 1694-1700